Pre-treatment haemoglobin level predicts response and survival after TPF induction polychemotherapy in advanced head and neck cancer patients

Clinical Otolaryngology

Volumn 33, Issue 3, 2008, Pages 245-251

  Baghi, M ^a   Wagenblast, J ^a   Hambek, M ^a   Moertel, S ^a   Gstoettner, W ^a   Strebhardt, K ^a   Knecht, R ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; HEMOGLOBIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; FEMALE; HAZARD RATIO; HEAD AND NECK CANCER; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; ONCOLOGY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 44849118904     PISSN: 17494478     EISSN: 17494486     Source Type: Journal    
DOI: 10.1111/j.1749-4486.2008.01702.x     Document Type: Article

References (20)

1. Lefebvre J.L. (2005) Current clinical outcomes demand new treatment options for SCCHN. Ann. Oncol. 16 (Suppl. 6 vi7 vi12
2. Lefebvre J.L., Chevalier D., Luboinski B. et al. (1996) Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J. Natl Cancer Inst. 88, 890 899
3. Schrijvers D., Van Herpen C., Kerger J. et al. (2004) Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. Ann. Oncol. 15, 638 645
4. Janinis J., Papadakou M., Xidakis E. et al. (2000) Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. Am. J. Clin. Oncol. 23, 128 131
5. Van Belle S.J. Cocquyt V. (2003) Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit. Rev. Oncol. Hematol. 47, 1 11
6. Knecht R., Baghi M., Hambek M. et al. (2003) Response rate and outcome of a novel induction chemotherapy regimen (TPF) in the first-line therapy of advanced head and neck carcinomas (SCCHN). Proc. Am. Soc. Clin. Oncol. 22, 501
7. Knecht R., Tesch H., Baghi M. et al. (2004) Response rate and outcome of a novel first line therapy for advanced head and neck carcinoma. J. Clin. Oncol. 22 (July Supplement 5559
8. Adelstein D.J., Tan E.H. Lavertu P. (1996) Treatment of head and neck cancer: the role of chemotherapy. Crit. Rev. Oncol. Hematol. 24, 97 116
9. Wagner W., Hermann R., Hartlapp J. et al. (2000) Prognostic value of hemoglobin concentrations in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery. Strahlenther. Onkol. 176, 73 80
10. Fein D.A., Lee W.R., Hanlon A.L. et al. (1995) Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J. Clin. Oncol. 13, 2077 2083
11. Glaser C.M., Millesi W., Kornek G.V. et al. (2001) Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int. J. Radiat. Oncol. Biol. Phys. 50, 705 715
12. Denis F. Lartigau E. (2004) Anaemia and radiation therapy. Cancer Radiother. 8 (Suppl. 1 S14 S23
13. Dusenbery K.E., McGuire W.A., Holt P.J. et al. (1994) Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 29, 1079 1084
14. Mercadante S., Gebbia V., Marrazzo A. et al. (2000) Anaemia in cancer: pathophysiology and treatment. Cancer Treat. Rev. 26, 303 311
15. Oken M.M., Creech R.H., Tormey D.C. et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5, 649 655
16. Miller A.B., Hoogstraten B., Staquet M. et al. (1981) Reporting results of cancer treatment. Cancer 47, 207 214
17. Dubray B., Mosseri V., Brunin F. et al. (1996) Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology 201, 553 558
18. Dunst J., Stadler P., Becker A. et al. (2001) Tumor hypoxia and systemic levels of vascular endothelial growth factor (VEGF) in head and neck cancers. Strahlenther. Onkol. 177, 469 473
19. Dunst J., Becker A., Lautenschlager C. et al. (2002) Anemia and elevated systemic levels of vascular endothelial growth factor (VEGF). Strahlenther. Onkol. 178, 436 441
20. Caro J.J., Salas M., Ward A. et al. (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91, 2214 2221